JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2026, Vol. 28 ›› Issue (5): 828-836.DOI: 10.3969/j.issn.1671-2587.2026.05.022
Previous Articles Next Articles
WU Ling, GAN Xinyu, TAN Qiang, REN Lina, PENG Tao
Received:2026-09-02
Revised:2026-09-22
Online:2026-10-20
Published:2026-11-11
CLC Number:
WU Ling, GAN Xinyu, TAN Qiang, REN Lina, PENG Tao. Transfusion-Related Risks in Patients with Chronic Kidney Disease: A Systematic Overview and Clinical Management Strategies[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(5): 828-836.
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.lcsxyjy.com/EN/10.3969/j.issn.1671-2587.2026.05.022
| [1] Gill K S,Muntner P,Lafayette R A,et al.Red blood cell transfusion use in patients with chronic kidney disease[J]. Nephrol Dial Transplant,2013,28(6):1504-1515. [2] Collins A J,Monda K L,Molony J T,et al.Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion[J]. Am J Kidney Dis,2014, 63(6):997-1006. [3] Cappell K A,Shreay S,Cao Z,et al.Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels[J]. BMC Nephrol,2014, 15:116. [4] Pavlou E G,Georgatzakou H T,Fortis S P,et al.Coagulation abnormalities in renal pathology of chronic kidney disease: the interplay between blood cells and soluble factors[J]. Biomolecules,2021,11(9):1309. [5] Hendrickson J E,Hillyer C D.Noninfectious serious hazards of transfusion[J]. Anesth Analg,2009,108(3): 759-769. [6] De La Vega-Méndez F M,Estrada M I,Zuno-Reyes E E, et al. Blood transfusion reactions and risk of acute kidney injury and major adverse kidney events[J]. J Nephrol, 2024,37(4):951-960. [7] 马志军,程连赛,武永胜,等. 临床输血不良反应发生率及其下降原因[J]. 临床血液学杂志,2015,28(6):499-501. [8] 马砚敏,张涛. 肾功能不全患者血液透析后输血反应的观察与分析[J]. 中国实用医药,2015,10(8):125-126. [9] Bulle E B,Klanderman R B,Pendergrast J,et al.The recipe for TACO: A narrative review on the pathophysiology and potential mitigation strategies of transfusion-associated circulatory overload[J]. Blood Rev,2022,52:100891. [10] Kapur R.Key features of the underlying pathophysiology of Transfusion-related acute lung injury[J]. Expert Rev Hematol,2025,18(1):57-64. [11] Chan B,Varghese A,Badve S V,et al.Systematic review of the effects of iron on cardiovascular,kidney,and safety outcomes in patients with CKD[J]. Kidney Int Rep,2025, 10(4):1037-1049. [12] Eschbach J W,Adamson J W.Iron overload in renal failure patients: Changes since the introduction of erythropoietin therapy[J]. Kidney Int,1999,55:S35-S43. [13] Rostoker G,Vaziri N D.Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations[J]. Heliyon,2019,5(7): e02045. [14] Rostoker G.When should iron supplementation in dialysis patients be avoided,minimized or withdrawn?[J]. Semin Dial,2019,32(1):22-29. [15] Piccin A,Cronin M,Brady R,et al.Transfusion-associated circulatory overload in Ireland: a review of cases reported to the National Haemovigilance Office 2000 to 2010[J]. Transfusion,2015,55(6):1223-1230. [16] Li G X,Rachmale S,Kojicic M,et al.Incidence and transfusion risk factors for transfusion-associated circulatory overload among medical intensive care unit patients[J]. Transfusion,2011,51(2):338-343. [17] Soni L,Saeed S,Cserti-Gazdewich C,et al.Mortality-associated risk factors for transfusion-associated circulatory overload[J]. Vox Sang,2024,119(9):996-1000. [18] Marshall A L,Levine M,Howell M L,et al.Dose‐associated pulmonary complication rates after fresh frozen plasma administration for warfarin reversal[J]. J Thromb Haemost,2016,14(2):324-330. [19] White S K,Walker B S,Schmidt R L,et al.The incidence of transfusion-related acute lung injury using active surveillance: A systematic review and meta-analysis[J]. Transfusion,2024,64(2):289-300. [20] Toy P,Looney M R,Popovsky M,et al.Transfusion-related acute lung injury: 36 years of progress (1985—2021)[J]. Ann Am Thorac Soc,2022,19(5):705-712. [21] Triulzi D J.Transfusion-related acute lung injury: current concepts for the clinician[J]. Anesth Analg,2009, 108(3):770-776. [22] Benson A B,Moss M,Silliman C C.Transfusion-related acute lung injury (TRALI): a clinical review with emphasis on the critically ill[J]. Br J Haematol,2009, 147(4):431-443. [23] Israelyan N,Vege S,Friedman D F,et al.RH genotypes and red cell alloimmunization rates in chronically transfused patients with sickle cell disease: A multisite study in the USA[J]. Transfusion,2024,64(3):526-535. [24] Habibi B,Lecolier B.Inconvenience of planned prophylaxis of transfusion-induced alloimmunization to red cells in chronic renal insufficiency[J]. Rev Fr Transfus Immunohematol,1983,26(3):267-277. [25] Nebie K,Sawadogo S,Sawadogo S,et al.Red blood cell alloimmunisation in multi-transfused patients from an haemodialysis service in Burkina Faso[J]. Afr J Lab Med,2022,11(1):1625. [26] Hung S Y,Hung I H,Yang Y T,et al.Frequent transfusion and specific HLA-DRB1 alleles correlate independently with Miltenberger blood group alloimmunization in dialysis patients[J]. HLA,2020,96(2):186-191. [27] Fonseca H E,Chiba A K,Fabron Junior A,et al.Anti-N-like and anti-Form red cell antibodies in chronic hemodialysis patients[J]. Ren Fail,2004,26(5):553-556. [28] 侯瑞琴,杨洪燕,崔银平,等. 患者不规则抗体鉴定结果分析及其临床意义[J]. 中国实验血液学杂志,2020,28(3): 961-966. [29] 李小飞,马春娅,蔡晓红,等. 红细胞血型抗原拓展匹配适用范围中国专家共识[J]. 临床输血与检验,2024,26(3): 289-298. [30] Tanhehco Y C,Berns J S.Red blood cell transfusion risks in patients with end-stage renal disease[J]. Semin Dial,2012,25(5):539-544. [31] Gaweda A E,Ginzburg Y Z,Chait Y,et al.Iron dosing in kidney disease: inconsistency of evidence and clinical practice[J]. Nephrol Dial Transplant,2015,30(2):187-196. [32] Fong I W.Blood transfusion-associated infections in the twenty-first century: new challenges[M]//Current Trends and Concerns in Infectious Diseases. Cham:Springer International Publishing,2020:191-215. [33] Seifried E,Schmidt M.Sicherheit der blutprodukte-update 2024[J]. Transfusionsmedizin,2024,14(1):34-45. [34] Lelie N,Busch M,Kleinman S.Efficacy of different testing scenarios in reducing transfusion-transmitted hepatitis B virus (TT-HBV) infection risk[J]. Viruses, 2022,14(10):2263. [35] Liu W J,Yu C M,Chen Y Y,et al.Trends in donor infection profiles and residual risks of transfusion-transmitted human immunodeficiency virus,hepatitis C virus and hepatitis B virus after the implementation of universal mini-pool nucleic acid testing in Taiwan[J]. Vox Sang,2025,120(10):995-1003. [36] Kühn J E.Transfusion-associated infections with cytomegalovirus and other human herpesviruses[J]. Infusionsther Transfusionsmed,2000,27(3):138-143. [37] Ziemann M,Hennig H.Prevention of transfusion-transmitted cytomegalovirus infections: which is the optimal strategy?[J]. Transfus Med Hemother,2014,41(1): 40-44. [38] Moreira-Soto A,Postigo-Hidalgo I,Tabares X,et al.Transfusion-transmitted infections: risks and mitigation strategies for Oropouche virus and other emerging arboviruses in Latin America and the Caribbean[J]. Lancet Reg Health Am,2025,46:101089. [39] Kopolovic I,Ostro J,Tsubota H,et al.A systematic review of transfusion-associated graft-versus-host disease[J]. Blood,2015,126(3):406-414. [40] Manduzio P.Transfusion-associated graft-versus-host disease: A concise review[J]. Hematol Rep,2018,10(4): 7724. [41] Baaten C C F M J,Sternkopf M,Henning T,et al. Platelet function in CKD: a systematic review and meta-analysis[J]. JASN,2021,32(7):1583-1598. [42] Lutz J, Jurk K.Platelets in advanced chronic kidney disease: two sides of the coin[J]. Semin Thromb Hemost, 2020,46(3):342-356. [43] Haysom R,Aziz N,Swan D,et al.Bleeding in patients with renal impairment: a current perspective[J]. Semin Thromb Hemost,2026,52(6):645-652. [44] Carminita E,Camacho V,Branfield S,et al.Platelet dysfunction in chronic kidney disease arises from bone marrow remodeling and megakaryocyte reprogramming[J]. Blood Adv,2026,10(5):1444-1456. [45] Ali S,Botnarciuc M,Daba L C,et al.Efficiency of platelet transfusion in patients with moderate-to-severe chronic kidney disease and thrombocytopenia[J]. Int J Mol Sci,2023,24(21):15895. [46] 维持性血液透析合并肾性贫血临床管理中国专家共识(2026版)工作组. 维持性血液透析合并肾性贫血临床管理中国专家共识(2026版)[J]. 中国血液净化,2026,25(5): 353-369. [47] Pothacamuri M A,Venugopal A,Chandrashekar N,et al.Erythropoiesis-stimulating agents (ESAs) in chronic kidney disease and cancer-related anemia: a narrative review of literature[J]. Cureus,2025,17(9):e93584. [48] CHUNG E Y M, PALMER S C, SAGLIMBENE V M, et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis[J]. Cochrane Database of Systematic Reviews, 2023(2):CD010590. [49] Singh A K,Carroll K,Perkovic V,et al.Daprodustat for the treatment of anemia in patients undergoing dialysis[J]. N Engl J Med,2021,385(25):2325-2335. [50] Toka H R,Bernardo M,Burke S K,et al. Vadadustat three times weekly in patients with anemia due to dialysis-dependent CKD[J]. Am J Kidney Dis,2025,85(4):454-464.e1. [51] TYAGI J, KAUR M, INGALE S, et al.Hypoxia-inducible factor prolyl hydroxylase inhibitors for anemia in dialysis-dependent chronic kidney disease: systematic review and meta-analysis of randomized controlled trials[J]. Indian Journal of Nephrology,2025, 35(2):198-216. [52] Stoumpos S,Crowe K,Sarafidis P,et al.Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association[J]. Nephrol Dial Transpl,2024,39(10): 1710-1730. [53] Kidney Disease:Improving Global Outcomes KDIGO Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease[J]. Kidney Int Suppl,2012,2(4):S279-S335. [54] del Vecchio L,Cases A,Eisenga M F,et al. KDIGO 2026 clinical practice guideline for anemia in chronic kidney disease (CKD): a commentary from the European renal best practice (ERBP)[J]. Nephrol Dial Transplant,2026, 41(8):1554-1572. [55] 中国医师协会肾脏内科医师分会肾性贫血指南工作组,陈香美,孙雪峰. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志,2021,101(20):1463-1502. [56] Franchini M,Marano G,Veropalumbo E,et al.Patient Blood Management: a revolutionary approach to transfusion medicine[J]. Blood Transfus,2019,17(3):191-195. [57] Butcher A,Richards T.Cornerstones of patient blood management in surgery[J]. Transfus Med,2018,28(2): 150-157. [58] Céspedes I C,Figueiredo M S,Hossne Junior N A,et al. Patient blood management program implementation: comprehensive recommendations and practical strategies[J]. Braz J Cardiovasc Surg,2024,39(5):e20240205. [59] Shander A,Van Aken H,Colomina M J,et al.Patient blood management in Europe[J]. Br J Anaesth,2012,109(1): 55-68. [60] Schonewille H,van de Watering L M,Brand A. Additional red blood cell alloantibodies after blood transfusions in a nonhematologic alloimmunized patient cohort: is it time to take precautionary measures?[J]. Transfusion,2006,46(4):630-635. [61] 中华人民共和国国家卫生健康委员会. WS/T 622—2018 内科输血[S]. 2018. [62] 中华人民共和国国家卫生健康委员会. WS/T 623—2018 全血和成分血使用[S]. 2018. [63] 中华人民共和国国家卫生健康委员会. WS/T 624—2018 输血反应分类[S]. 2018. |
| [1] | LI Jinqi, XIA Lili, LIU Jiayi, ZHOU Mei, WANG Xingyi, GU Haihui. Analysis on the Safety and Efficacy of Perioperative Transfusion of Frozen-Thawed Deglycerolized Red Blood Cells in Patients with Solid Tumors [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(5): 711-716. |
| [2] | YU Jian, LI Xinglong, TU Jiaxin, BAO Likun, ZHU Changtai. A Large-Scale Quantitative Model of RhCE-Related Transfusion Alloimmunization Risk in the Chinese Population [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(5): 733-739. |
| [3] | SONG Wenqian, YU Wanzhen, BAI Suning, WANG Liying, SHAO Linnan, ZHOU Shihang, LIANG Xiaohua. Association of HLA-Ⅱ Gene Polymorphisms with Red Blood Cell Alloimmunization [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(5): 774-781. |
| [4] | CHEN Linfeng, HUA Baolai. Recent Advances in Mechanisms of Erythrocyte Programmed Death and Their Pathophysiological Significance [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(5): 874-881. |
| [5] | CHEN Yujia, JIANG Yi, SHEN Xing, YU Jinfeng, FAN Fudong, CHEN Qing. Study on Preoperative Anemia Correction Strategy and Correction Magnitude in Patients Undergoing Cardiac Valve Surgery and Their Association with Prognosis [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(3): 345-354. |
| [6] | Writing Group of Expert Consensus on the Clinical Diagnosis, Treatment of Transfusion-associated Circulatory Overload, Working Party on Clinical Transfusion, Chinese Society of Blood Transfusion. Expert Consensus on the Clinical Diagnosis and Treatment of Transfusion-associated Circulatory Overload (2026 Edition) [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(1): 1-8. |
| [7] | CHEN Yuye, SHAN Jiachen, GAO Jie, GAO Yuan, SHI Jia, JI Hongwen. Progress in Preoperative Anemia Intervention Research for Adult Cardiac Surgery [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(6): 867-876. |
| [8] | LI Jiyang, LI Chenyan, ZHOU Qianqian, ZHAN Linsheng. A Novel Animal Model for Red Blood Cell Alloimmunization [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(3): 340-346. |
| [9] | LIANG Chunyan, DUAN Li, LIU Youying, LIU Fangjiu. Risk Factors and Predictive Models of Transfusion-associated Circulatory Overload in Hospitalized Patients [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 771-776. |
| [10] | JIANG Xueyu, YANG Yiming, SUN Juan, XIE Rufeng, GAO Li, YANG Jie. Pretreatment with Baicalin Reduces the Production of IgG and IgM in a Mouse Model of Red Blood Cell Infusion [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(5): 604-608. |
| [11] | PU Youwei, HU Xue, LUO Jinlian, YU Zebo. Research Progress in Treatment of Aplastic Anemia with Traditional Chinese Medicine [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(5): 715-720. |
| [12] | CHEN Yan, CHEN Linfeng, HE Xin, WANG Yan, YU Wenjuan, LIU Xuan, LIU Siqi. Factors Influencing Perioperative Blood Transfusions in Patients with Colorectal Cancer: Single-Center Data from 2013 To 2020 [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(1): 79-85. |
| [13] | CHEN Shan, LIU Jingfu, LI Zhen, et al. Establishment of A Blood Transfusion Prediction Model for Perioperative Patients with Esophageal Cancer [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(6): 743-748. |
| [14] | LU Xia, PAN Yingfang, ZHAO Aiping, et al. High-titer Anti-D Alloimmunization Shortly after Transfusion of “Asia type” DEL Red Blood Cells in an RhD Negative Patient [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(6): 835-838. |
| [15] | GAO Yuan, GAO Xurong, GAO Jie, et al. Research Advances in the Prevention and Treatment of Perioperative Anemia in Patients Undergoing Coronary Artery Bypass Grafting [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(4): 555-558. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
